Spruce Biosciences Analyst Ratings
RBC Capital Maintains Spruce Biosciences(SPRB.US) With Hold Rating, Maintains Target Price $2
RBC Capital Sticks to Their Hold Rating for Spruce Biosciences (SPRB)
JMP Securities Maintains Spruce Biosciences(SPRB.US) With Buy Rating, Maintains Target Price $3
JMP Securities Maintains Spruce Biosciences(SPRB.US) With Buy Rating, Maintains Target Price $3
Analysts Offer Insights on Healthcare Companies: Pyxis Oncology (PYXS), Spruce Biosciences (SPRB) and Envista Holdings (NVST)
Spruce Biosciences Analyst Ratings
Analysts' Opinions Are Mixed on These Healthcare Stocks: Kronos Bio (KRON), Spruce Biosciences (SPRB) and ScPharmaceuticals (SCPH)
H.C. Wainwright Maintains Spruce Biosciences(SPRB.US) With Hold Rating
RBC Capital Reiterates Sector Perform on Spruce Biosciences, Maintains $2 Price Target
Spruce Biosciences Analyst Ratings
RBC Capital Maintains Spruce Biosciences(SPRB.US) With Hold Rating, Maintains Target Price $2
Analysts Offer Insights on Healthcare Companies: Meiragtx Holdings (MGTX), Spruce Biosciences (SPRB) and Gossamer Bio (GOSS)
Buy Rating Affirmed for Spruce Biosciences Amid Anticipated Positive Clinical Trial Outcomes and Strong Financial Position
JMP Securities Maintains Spruce Biosciences(SPRB.US) With Buy Rating, Maintains Target Price $3
Spruce Biosciences Analyst Ratings
Spruce Biosciences Analyst Ratings
Hold Rating on Spruce Biosciences Amid Clinical Trial Uncertainties and Rising Competition
Buy Rating Affirmed for Spruce Biosciences Amid Upcoming Trial Data and Strong Financial Position
Spruce Biosciences Analyst Ratings